In a new take on targeted radionuclide therapy, engineered bacteria injected into tumours attract beta-emitting radiopharmaceuticals to kill the cancer cells
Sensing device could be used to detect a variety of chemical tracers, including those produced by patients with conditions such as asthma and kidney disease